AstraZeneca to lay off 550 in Wilmington Philadelphia Business Journal - by John George Staff Writer Send this story to a friend Email address of friend (insert comma between multiple addresses): Your email address: Add a brief note:
Enter words from the security image above:
Get new image | Image verificationAudio verification | reCAPTCHA™ Related News
* Atlas Venture racks up exit in Astra deal * AstraZeneca layoffs to affect 8,000 as company grapples with generics * Targacept banks $200M payment
AstraZeneca announced plans to lay off about 550 workers in research and development at its U.S. headquarters in Wilmington, Del.
The job cuts will occur over the next two years and are part of the job reduction plan outlined by the pharmaceutical company in January, which set a goal of eliminating 15,000 positions over the next five years.
AstraZeneca (NYSE:AZN), based in London, has about 4,500 workers in Delaware, at the U.S. headquarters site and at a manufacturing plant in Newark.
Company officials said the Wilmington site will no longer conduct early-stage drug-discovery research, but it will continue to be involved in late-stage global medicines development.
AstraZeneca has 65,000 employees worldwide.
